Daxor will highlight its FDA 510 (k)-cleared, next-generation, lab-based BVA platform. Operating 3x faster than its predecessor, requiring 50% less sample volume, and delivering >95% measurement ...
Whether fans are heading to Georgia Theatre, The Eastern, Variety Playhouse, or Terminal West, the sweepstakes brings together what SweetWater does best: cold beer, live music, and good times with ...
Cetuximab will be supplied by Merck KGaA, Darmstadt, Germany for the Australia and China trial sites SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd.
Company remains on track to report interim results from Phase 2b cohort in 4Q 2026. NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinic ...
The event will feature John Affeldt, MD, from Loma Linda University Health, a leading expert in limbal stem cell deficiency (LSCD), who will join company management to discuss: The unmet need and ...
FDA accepted the resubmission as complete and classified it as a Class 2 response; Prescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027; Ex-U.S. strategy ...
Poster Details Number: P-22 Title: SER-428, an Investigational Live Biotherapeutic Product (LBP) with a Novel Liquid Formulation, for Reduction of Bloodstream Infections in High-Risk Patients after ...
ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...
Agentic AI refers to artificial intelligence systems designed to autonomously plan and execute tasks to achieve defined objectives. SciSparc aims to build on its scientific and technical foundation to ...
IRulya Therapeutics Inc. (Nasdaq: IRLA), a clinical stage biopharmaceutical company focused on the development of novel, disease modifying therapeutics for serious underserved diseases, today ...
TNX-801 Presentation Details Title: TNX-801 Vaccine Platform Safety and Efficacy Date & Time: Oct. 21, 2026, 1:15 p.m. CEST Session Category: Emerging & Infectious Diseases Presenter: Farooq Nasar, Ph ...
First Tracks Biotherapeutics intends to use the proceeds from the private placement for general corporate purposes, including for clinical development of ANB033, a CD122 antagonist. Leerink Partners, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results